Overview
Biotech firm's Q4 revenue and net income missed analyst expectations
Company appointed Randy Teel, Ph.D., as new CEO
Company highlighted progress in clinical trials and pipeline developments
Outlook
Arvinas expects cash reserves to support operations into the second half of 2028
Company plans Phase 1 trial for ARV-6723 in mid-2026
Arvinas and Pfizer aim for vepdegestrant PDUFA action date on June 5, 2026
Result Drivers
CLINICAL TRIAL PROGRESS - Arvinas highlighted significant progress in its clinical trials, including the acceptance of ARV-102 data for an oral presentation at a major conference and the initiation of a first-in-human trial for ARV-027
R&D EXPENSES - Decrease in R&D expenses attributed to reduced personnel costs and external expenses, while continuing development of PROTAC drug candidates
PIPELINE DEVELOPMENTS - Arvinas emphasized the ongoing development of its PROTAC drug candidates, including ARV-806 and ARV-393, with notable preclinical and clinical advancements
Company press release: ID:nGNX1BKWLY
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $9.50 mln | $34.88 mln (13 Analysts) |
Q4 Net Income | Miss | -$67.40 mln | -$40.62 mln (12 Analysts) |
Q4 Operating income | Miss | -$74.60 mln | -$44.75 mln (14 Analysts) |
Q4 Pretax Profit | Miss | -$67.20 mln | -$38.15 mln (12 Analysts) |
Q4 Operating Expenses | $84.10 mln |
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)